Novartis Ag (NVS) EBT Margin Growth (3y) (2012 - 2026)
Novartis Ag (NVS) EBT Margin Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -265.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 636.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 3,137.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 625.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -10.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 443.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -15,548.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -6,936.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -2,347.00 |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 456.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 625.00 |
| Jun 30, 2025 | 1,626.00 |
| Dec 31, 2024 | 516.00 |
| Jun 30, 2024 | 364.00 |
| Dec 31, 2023 | 259.00 |
| Jun 30, 2023 | 322.00 |
| Mar 31, 2023 | 154.34 Mn |
| Jun 30, 2022 | -641.00 |
| Mar 31, 2022 | 1.32 Bn |
| Dec 31, 2021 | -97,871.00 |
| Sep 30, 2021 | -354,942.00 |
| Jun 30, 2021 | -4,487.00 |
| Mar 31, 2021 | 498.22 Mn |
| Dec 31, 2020 | 1,531.00 |
| Sep 30, 2020 | 756.34 Mn |
| Jun 30, 2020 | 125.00 |
| Mar 31, 2020 | -75,794.00 |
| Jun 30, 2019 | -81,283.00 |
| Mar 31, 2019 | -18.31 Bn |
| Dec 31, 2018 | 66,989.00 |